Cancer screening with amino acid PET has already been validated for adults, but it has now been deemed a powerful tool for tumor localization in children and young adults, according to a study published Sept. 19 in the Journal of Nuclear Medicine . {read more here}

The National Multiple Sclerosis Society today announced that it has entered into a research collaboration agreement with GE Healthcare through Fast Forward, a not for profit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the United Kingdom, is aimed to aid in physicians’ understanding whether imaging neuroinflammation in MS patients before and after treatment with natalizumab (Tysabri^®)* can help identify which patients may respond to treatment. {read more here}